Immunocompromised mice transplanted with KRAS mutated tumor cells were treated daily with afatinib (20 mg/kg), tozasertib (75 mg/kg), or the combination starting two days after engraftment and continuing for 19 days. The gene discussed is KRAS; the disease is neoplasm.